/ /

  • linkedin
  • Increase Font
  • Sharebar

    Low-dose ranibizumab effective for retinopathy of prematurity

    A low dose of ranibizumab (Lucentis, Genentech/Roche) works well as a treatment for retinopathy of prematurity (ROP), researchers say.

    A 0.12-mg dose of the anti-vascular endothelial growth factor (VEGF) drug prevented the need for laser photocoagulation or retreatment for at least 24 weeks without suppressing plasma VEGF levels, reported Dr Andreas Stahl of the University of Freiburg in Germany, and colleagues, in JAMA Pediatrics.

    The treatment could offer an attractive alternative to bevacizumab (Avastin, Genentech/Roche), which has been shown to halt the progression of severe ROP but suppresses VEGF plasma levels below the limit of detection for weeks, the researchers wrote.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results